A Rare Case of Non-Prosthetic Aortic Valve Infectious Endocarditis Caused by *Achromobacter xylosoxidans*

**Patient:** Male, 19-year-old

**Final Diagnosis:** Endocarditis

**Symptoms:** Fever • weight loss

**Medication:** —

**Clinical Procedure:** —

**Specialty:** Cardiology

**Objective:** Rare disease

**Background:** *Achromobacter xylosoxidans* is a ubiquitous environmental gram-negative bacterium, very resistant to antibiotics. Endocarditis caused by these bacteria is extremely rare, with only 20 cases described in the literature to our knowledge. Mortality rates are high, and treatment usually involves a combination of antibiotics and surgery. Nosocomial infections predominate with a strong association between bacteremia and immunosuppression.

**Case Report:** A 19-year-old immunocompetent male presented with endocarditis. He had interatrial and interventricular communication corrected at age 11 months and aortic coarctation correction at age 10. Initial echocardiogram showed a possible interventricular patch infection, which was later ruled out. He was treated initially for endocarditis with a combination of antibiotics, but because he remained febrile after appropriate antibiotic treatment, surgery was performed. The patient had a favorable outcome after surgery and was asymptomatic on follow-up.

**Conclusions:** Endocarditis caused by *A. xylosoxidans* is extremely rare. To date, only 20 cases of IT have been reported in the literature, of which only two involved a native valve. Given the scarcity of cases reported, there is no consensus on the best treatment.

**MeSH Keywords:** *Achromobacter denitrificans • Endocarditis, Bacterial • Heart Valves*

**Full-text PDF:** [https://www.amjcaserep.com/abstract/index/idArt/923031](https://www.amjcaserep.com/abstract/index/idArt/923031)
**Background**

*Achromobacter xylosoxidans* is a ubiquitous, environmental gram-negative bacterium, very resistant to antibiotics. Endocarditis caused by these bacteria is extremely rare, with only 20 cases described in the literature to our knowledge. Mortality rates are high [1], and treatment usually involves a combination of antibiotics and surgery. Nosocomial infections predominate with a strong association between bacteremia and immunosuppression [2]. Here, we present a case of endocarditis caused by these uncommon bacteria in the native valve in an immunocompetent patient with no recent hospitalizations and a history of cardiac surgery, who survived after a combination of surgical and antibiotic treatment.

**Case Report**

A 19-year-old man presented with a history of approximately 1 month of intermittent fevers, chills, dry cough, and pleuritic chest pain. He lost about 10 lb during this period and had progressive fatigue. He had a medical history of interatrial and interventricular communication corrected at 11 months of age and aortic coarctation correction at age 10. On examination, the patient was febrile, tachycardic, and his blood pressure was 125 over 76 mmHg. Physical exam demonstrated diastolic aortic murmur, grade 3/6, compatible with aortic insufficiency. There was no jugular vein distention, and there were no petechiae or signs of skin lesions. The rest of the patient’s physical exam was normal. Laboratory testing revealed an elevated white blood cell count of 16.45 $\times 10^9$/L and microcytic anemia with hemoglobin of 9.1 g/dL and mean corpuscular volume of 78 fl. Creatinine was 0.71 mg/dL with a glomerular filtration rate above 60 mL/min. An HIV test done on our patient was negative. Chest x-ray showed signs of mild pulmonary congestion and an enlarged cardiac silhouette. An echocardiogram revealed a moderate left atrium enlargement and eccentric left ventricular hypertrophy with an ejection fraction of 47%. A filamentous structure was also seen inside the patient’s left ventricle, adherent to a bicuspid aortic valve, and the ventricular patch in his inter-ventricular septum and severe aortic insufficiency. A diagnosis of endocarditis was given and the patient was placed on gentamicin, oxacillin, and ceftriaxone.

Two sets of blood cultures collected on the patient’s admission were positive for presence of *Achromobacter xylosoxidans* sensitive only to carbapenem with minimum inhibitory concentrations (MIC) of 0.5 and resistant to oxacillin and ceftriaxone MIC 16 for both. The antibiotics were switched but the patient continued to have fevers after 7 days of appropriate antibiotics associated with increased shortness of breath and lung congestion compatible with acute heart failure. Subsequent blood cultures performed on Day 5 of antibiotics were still positive. Because of the patient’s clinical non-response and acute-onset heart failure associated with aortic insufficiency, a surgical procedure was scheduled [3].

During the surgery, vegetation was seen on the patient’s aortic valve but not on his ventricular patch. Culture of the vegetation showed *A. xylosoxidans*. The surgery was done with no major complications. He went to intensive care on moderate doses of vasopressors and was extubated 12 hours after the procedure.

On the fourth day of the patient’s hospitalization, he had a spontaneous right-sided pneumothorax, with no apparent cause, which was drained and resolved after 3 days. He went home 10 days after surgery and completed 28 days of carbapenem. His immediate and 30-day echocardiograms at follow-up did not show any vegetation. He was symptomatic at his 6-month and 1-year follow-up appointments.

**Discussion**

Endocarditis is dangerous and difficult to treat. Prolonged fevers with weight loss in patients with a previous history of heart disease, especially after cardiac surgeries, should raise suspicion of this diagnosis.

*A. xylosoxidans* is an aerobic, motile, gram-negative rod that was first described in 1971 by Yabuuchi and Ohyama, who discovered it in patients with chronic, purulent otitis media [4]. Infections with *A. xylosoxidans* have included meningitis, pneumonia, peritonitis, and urinary tract infections [5,6]. However, bacteremia associated with prosthetic or native valve endocarditis caused by *A. xylosoxidans* is rare.

A recent review published by Barragan, et al. showed that in the majority of cases, patients were immunocompromised and almost all had acquired their infections in the hospital [7]. Reviewing our patient’s records, he had no history of recent or recurrent illnesses or hospitalizations. In most patients, infections associated with this pathogen are related to catheters [7,8] but in our report, we do not have a clear source of his infection.

To date, only 20 cases (Table 1) of *A. xylosoxidans* endocarditis have been reported in the literature, of which only two involved a native valve [8–28]. Considering the treatment and outcome: 11 of 19 (58%) required surgical intervention; 8 of 17 (47%) died, 2 of the 8 deaths (22%) were from the operated group and the other 6 (75%) were from the clinically treated group [10].
Given the scarcity of the cases reported, there is no consensus on the best treatment for *A. xylosoxidans* endocarditis. Antipseudomonal penicillin and carbapenems are the best choices, based on bacteriologic studies and case reports [11].

In contrast to use of a percutaneous atrial septal occluder device, surgical patch closure of atrial septal defects is known to represent no risk infective endocarditis [12]. To our knowledge, only two cases of endocarditis on a surgical patch of a ventricular septal defect have been reported [12]. Considering these previous case reports, it would be unlikely for our patient to have an infection in his patch. However, his bicuspid aortic valve increases his risk of developing endocarditis.

### Table 1. Reported cases of IE.

| Author          | Age | Risk of IE | Comorbidities | Valve | Prosthetic | Antibiotic                          | Surgery | Died |
|-----------------|-----|------------|---------------|-------|------------|-------------------------------------|---------|------|
| This case       | 19 y| CS, Bicuspid aortic valve | None | Ao | No | Meropenem | Yes | No |
| Levoy et al. [8]| 6 m | IVC+ calcified MV | Arterial calcification | M | No | Piperacillin-tazobactam+TMP-SMX | No | No |
| Tea et al. [9]  | 67 y| Rheumatic mitral stenosis, asplenia | Asplenia | M | No | Piperacillin-sulbactam+Imipenem | Yes | NA |
| Rodrigues et al. [10] | 86 y | None | IHD, lung fibrosis, CKD, polymyalgia | Ao | No | Piperacillin-tazobactam+TMP-SMX | No | No |
| Derber et al. [11] | 54 y | PV+ Fallot’s T | Fallot’s T | P | Yes | Piperacillin-tazobactam+Imipenem-Cilastatin | Yes | No |
| Kumar et al. [13] | 54 y | NA | CKD, CRF, H | M+Ao | No | Vancomycin+piperacillin-tazobactam+gentamicin | Yes | NA |
| Rafael et al. [14] | 50 y | CS | VSDR | P+RVOT | No | NA | Yes | No |
| Sawant et al. [15] | 62 y | PV+PM | AF, CHF, COPD, CKD | M+Ao+PM | Yes/No/– | Piperacillin-tazobactam+TMP-SMX+amikacin+meropenem+rifampicin | Yes | No |
| Tokuyasu et al. [16] | 86 y | PV | NA | Ao | Yes | Carbapenem | No | Yes |
| Store et al. [17] | 79 y | None | H, AF, TIA | M+Ao | No | Meropenem | No | Yes |
| Malek-Marín et al. [18] | 50 y | Catheter | CKD | NA | – | NA | Yes | Yes |
| Ahmed et al. [19] | 69 y | PV | DM, H, CKD, CABG | M+Ao | No/Yes | Ertapenem+Tigecycline+TMP-SMX | Yes | Yes |
| van Hal et al. [20] | 37 y | PV+IDU | NA | Ao | Yes | Carbapenem | Yes | No |
| Yang et al. [21] | 35 y | IDU+TR+MP | Hepatitis C | T | No | Piperacillin-tazobactam+Amikacin+Ceftazidime | Yes | NA |
| Nanuashvili et al. [22] | 46 y | None | DM, Emphysema, IS | M+Ao | No | Ampicillin+Sulbactam+Cotrimoxazole | Yes | No |
| Ahn et al. [23] | 35 y | CS+PM | VSDR, CHB with PM | PM+RVOT | – | Ceftazidime+Amikacin | Yes | No |
| Martino et al. [24] | 33 y | IVC | Bone marrow transplant | NA | – | Aztreonam+Amikacin | No | Yes |
| Davis et al. [25] | 30 y | NA | HF | NA | – | None | No | Yes |
AF – atrial fibrillation; Ao – aortic; CABG – coronary artery bypass grafting; CHB – complete heart block; CHF – congestive heart failure; CKD – chronic kidney disease; COPD – chronic obstructive pulmonary disease; CS – cardiac surgery; DM – diabetes mellitus; H – hypertension; HF – heart failure; IDU – intravenous drug user; IHD – ischemic heart disease; IS – ischemic stroke; IVC – intravenous catheter; M – mitral; NA – not available; P – pulmonary; PM – pacemaker; PV – prosthetic valve; RVOT – right ventricular outflow tract; T – tricuspid; TIA – transient ischemic accident; TMP-SMX – trimethoprim-sulfamethoxazole; TR – tricuspid regurgitation; VSDR – ventricular septal defect repair.

Conclusions

We presented an uncommon and rare case of *A. xylosoxidans* as the cause of infective endocarditis in a young, immunocompetent patient. The bacteria is very resistant and the treatment usually requires broad-spectrum antibiotics associated with surgical procedures. Our patient had a good outcome and was asymptomatic in later follow up.

Acknowledgments

We thank Dr. Lucia Belem for assistance in gathering data for the report.

References:

1. Xia R, Otto C, Zeng J et al: Achromobacter endocarditis in native cardiac valves – an autopsy case report and review of the literature. Cardiovasc Pathol, 2018; 36: 6–10
2. Manfredi R, Nanetti A, Ferri M, Chiiodo F: Bacteremia and respiratory involvement by *Alcaligenes xylosoxidans* in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis, 1997; 16(12): 933–38
3. Baddour LM, Wilson WR, Bayer AS et al: Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association: Circulation, 2015; 132: 1435–86
4. Ohyama A, Yabuuchi O: *Achromobacter* xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol, 1971; 15(70028): 477–81
5. Shigeta S, Yasunaga Y, Honzumi K et al: Cerebral ventriculitis associated with *Achromobacter* xylosoxidans. J Clin Pathol, 1978; 31(2): 156–61
6. Igra-Siegmund Y, Chmel H, Cobbs C: Clinical and laboratory characteristics of *Achromobacter xylosoxidans* infection. J Clin Microbiol, 1980; 11(2): 141–45
7. Barragán EP, Pérez JS, Corbella L et al: *Achromobacter xylosoxidans* bacteremia: Clinical and microbiological features in a 10-year case series. Rev Esp Quimioter, 2018; 31(3): 268–73
8. Levoy CS, Hall DJ, Berman D: *Achromobacter xylosoxidans* endocarditis and septic arthritis in an infant affected by generalized arterial calcification of infancy. JMM Case Rep, 2015; 2(6): 1–4
9. León J, Caruso M, Gary P et al: A koi diagnosis: *Achromobacter xylosoxidans* as an unusual cause of mitral valve endocarditis. J Am Coll Cardiol, 2019; 73(9 Suppl. 1): 2999
10. Rodrigues CG, Rays J, Kanegae MY: Native-valve endocarditis caused by *Achromobacter* xylosoxidans: A case report and review of literature. Autops Case Rep, 2017; 7(3): 50–55
11. Derber C, Elam K, Forbes BA, Bearman G: *Achromobacter* species endocarditis: A case report and literature review. Can J Infect Dis Med Microbiol, 2011; 22(3): e17–e20
12. Honnorat E, Seng P, Riberi A et al: Late infectious endocarditis of surgical patch closure of atrial septal defects diagnosed by 18F-fluorodeoxyglucose gated cardiac computed tomography (18F-FDG-PET/CT): A case report. BMC Res Notes, 2016; 9(1):16–19
13. Kumar S, Khaira J, Penigalapati D, Apurva A: Native Valve endocarditis in a dialysis patient by *Achromobacter* xylosoxidans: Rare pathogen. J Glob Infect Dis, 2017; 9(2): 85
14. Rafael AE, Keshavamurthy S, Sepulveda E et al: Intracardiac abscess with cutaneous fistula: Secondary to ventricular septal defect repair simulating sternal wound infection. Texas Hear Inst J, 2014; 41(5): 324–26
15. Sawant AC, Srivatsa SS, Castro LJ: *Alcaligenes xylosoxidans* endocarditis of a prosthetic valve and pacemaker: In a 62-year-old woman. Texas Hear Inst J, 2013; 40(1): 95–98
16. Tokuyasu H, Fukushima T, Nakazaki H, Shimizu E: Infective endocarditis caused by *Achromobacter* xylosoxidans: A case report and review of the literature. Intern Med, 2012; 51(9): 1133–38
17. Storey A, Wilson A, McWilliams E: Native valve infective endocarditis due to *Achromobacter* xylosoxidans in an apparently immunocompetent individual. BMJ Case Rep, 2010; 2010: bcr0620103104
18. Malek-Marín T, Arenas MD, Pérdigher M et al: A case of endocarditis of difficult diagnosis in dialysis: Could “pest” friends be involved? Clin Nephrol, 2009; 72(5): 405–9
19. Ahmed MS, Nistal C, Jayan R et al: *Achromobacter* xylosoxidans, an emerging pathogen in catheter-related infection in dialysis population causing prosthetic valve endocarditis: A case report and review of literature. Clin Nephrol, 2009; 71(3): 350–54
20. Van Hal S, Stark D, Marriott D, Harkness J: *Achromobacter xylosoxidans* subsp. *xylosoxidans* prosthetic aortic valve infective endocarditis and aortic root abscesses. J Med Microbiol, 2008; 57(4): 525–27
21. Yang CH, Shih NC, Lu DCT: Infective endocarditis due to *Achromobacter xylosoxidans* associated with spondylodiscitis: A case report. J Intern Med Taiwan, 2007; 18(4): 212–16
22. Nanuashvili A, Kacharava G, Jashlovshvili N: A case of native valve infective endocarditis caused by *Alcaligenes xylosoxidans*. Euro Surveill, 2007; 12(5): E070524.2
23. Ahn Y, Kim NH, Shin DH et al: Pacemaker lead endocarditis caused by *Achromobacter xylosoxidans*. J Korean Med Sci, 2004; 19(2): 291–93
24. Martino P, Micozzi A, Venditti M et al: Catheter-related right-sided endocarditis in bone marrow transplant recipients. Rev Infect Dis, 1990; 12(2): 250–57
25. Davis M, Gratten M, Ree GH: Infective endocarditis caused by *Actinobacillus actinomycetemcomitans* and *Achromobacter xylosoxidans*. PNG Med J, 1982; 25(1): 7–11
26. Lofgren RP, Nelson AE, Crossley KB: Prosthetic valve endocarditis due to *Achromobacter xylosoxidans*. Am Heart J, 1981; 101(4): 502
27. Bhattachari M, Papireddy M, Kulkarni S: A rare case of complicated *Achromobacter xylosoxidans* endocarditis and its successful management. J Hosp Med, 2016; 11(Suppl 1) http://www.shmabstracts.com/abstract/a-rare-case-of-complicated-achromobacter-xylosoxidans-endocarditis-and-its-successful-management
28. Isom DA, Hoeprich PD: Postoperative valve endocarditis due to *Achromobacter xylosoxidans*. West J Med, 1982; 136(2): 153–57